IL283937A - Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment - Google Patents

Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment

Info

Publication number
IL283937A
IL283937A IL283937A IL28393721A IL283937A IL 283937 A IL283937 A IL 283937A IL 283937 A IL283937 A IL 283937A IL 28393721 A IL28393721 A IL 28393721A IL 283937 A IL283937 A IL 283937A
Authority
IL
Israel
Prior art keywords
inhibitor
cdk4
cancer
treatment
combination therapy
Prior art date
Application number
IL283937A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL283937A publication Critical patent/IL283937A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL283937A 2018-12-20 2021-06-13 Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment IL283937A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782767P 2018-12-20 2018-12-20
US201962793128P 2019-01-16 2019-01-16
PCT/IB2019/060987 WO2020128878A1 (fr) 2018-12-20 2019-12-18 Polythérapie avec un inhibiteur de raf et un inhibiteur de cdk4/6 pour une utilisation dans le traitement du cancer

Publications (1)

Publication Number Publication Date
IL283937A true IL283937A (en) 2021-07-29

Family

ID=69165429

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283937A IL283937A (en) 2018-12-20 2021-06-13 Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment

Country Status (12)

Country Link
EP (1) EP3897591A1 (fr)
JP (1) JP2022514056A (fr)
KR (1) KR20210105388A (fr)
CN (1) CN113453671A (fr)
AU (1) AU2019407159A1 (fr)
BR (1) BR112021011699A2 (fr)
CA (1) CA3123510A1 (fr)
CL (1) CL2021001623A1 (fr)
IL (1) IL283937A (fr)
MX (1) MX2021007477A (fr)
TW (1) TW202038964A (fr)
WO (1) WO2020128878A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019003095A (es) 2016-09-19 2019-07-04 Novartis Ag Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk.
PT3618875T (pt) 2017-05-02 2023-08-07 Novartis Ag Terapia de combinação que compreende um inibidor de raf e trametinib
CN115551509A (zh) * 2020-05-12 2022-12-30 诺华股份有限公司 包含craf抑制剂的治疗组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN108348513A (zh) * 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
PT3618875T (pt) 2017-05-02 2023-08-07 Novartis Ag Terapia de combinação que compreende um inibidor de raf e trametinib

Also Published As

Publication number Publication date
TW202038964A (zh) 2020-11-01
CA3123510A1 (fr) 2020-06-25
EP3897591A1 (fr) 2021-10-27
BR112021011699A2 (pt) 2021-09-08
MX2021007477A (es) 2021-08-05
CL2021001623A1 (es) 2022-02-11
JP2022514056A (ja) 2022-02-09
WO2020128878A1 (fr) 2020-06-25
KR20210105388A (ko) 2021-08-26
CN113453671A (zh) 2021-09-28
AU2019407159A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
IL283937A (en) Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment
IL268305B2 (en) Palinabolin in combination with one or more G-CSF drugs for use in the drug treatment of docetaxel-induced neutropenia
IL273031A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
IL281999A (en) YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
IL289167A (en) The history of 2h-indazole and their use in the treatment of diseases
SG11202102338TA (en) Quinuclidine-3-one derivatives and their use in cancer treatment
IL284053A (en) New compounds and their use in therapy
IL286334A (en) Modified microRNAs and their use in cancer treatment
EP3897725A4 (fr) Combinaison de radioimmunothérapie et de thérapie de point de contrôle immunitaire dans le traitement du cancer
HK1257589A1 (zh) 預防和治療組織器官纖維化的藥物及其用途
IL277805A (en) Use of gaboksadol in the treatment of substance use disorders
PT3568397T (pt) Compostos e a sua utilização no tratamento da esquistossomose
IL269121A (en) Usl-311 for use in the treatment of cancer
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL290192A (en) Nitanin analogs and their use in the treatment of chronic and acute pain
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL277038A (en) Bexarotane derivatives and their use for cancer treatment
SG11202105276TA (en) Oligo-benzamide analogs and their use in cancer treatment
SG11202010906XA (en) R-fadrozole for use in the treatment of aldostonerism
EP3697413A4 (fr) Thérapie combinatoire de rayonnements fractionnés et de sapc-dops pour le traitement de tumeurs
GB2581035B (en) Novel compounds and their use in therapy
HUP1900281A1 (hu) Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra
EP4025304C0 (fr) Dérivés de thioridazine et leur utilisation pour le traitement du cancer